RNU6-1088P

Across TCGA pan-cancer cohorts, RNU6-1088P RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RNU6-1088P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where RNU6-1088P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6-1088P is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

KIRP, PRAD, and LUSC are the cancer types where RNU6-1088P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-1088P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	III,IV	+0.228	.044	2	view →
PRAD	All	All	+0.138	.025	2	view →
LUSC	All	All	+0.134	.009	2	view →
LIHC	All	All	+0.077	.021	2	view →
KICH	All	II,III,IV	+0.150	.044	1	view →
THCA	All	All	−0.092	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RNU6-1088P–KIRP

Open the KIRP breakdown →